News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
284,134 Results
Type
Article (15321)
Company Profile (300)
Press Release (268507)
Multimedia
Podcasts (80)
Webinars (12)
Section
Business (80394)
Career Advice (204)
Deals (13414)
Drug Delivery (43)
Drug Development (50846)
Employer Resources (34)
FDA (5873)
Job Trends (5253)
News (146008)
Policy (10216)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (954)
Accelerated approval (20)
Adcomms (14)
Allergies (86)
Alliances (21911)
ALS (128)
Alzheimer's disease (1042)
Antibody-drug conjugate (ADC) (244)
Approvals (6068)
Artificial intelligence (272)
Autoimmune disease (119)
Automation (9)
Bankruptcy (106)
Best Places to Work (4609)
BIOSECURE Act (7)
Biosimilars (102)
Biotechnology (231)
Bladder cancer (102)
Brain cancer (47)
Breast cancer (351)
Cancer (3175)
Cardiovascular disease (239)
Career advice (181)
Career pathing (8)
CAR-T (225)
CDC (6)
Cell therapy (581)
Cervical cancer (15)
Clinical research (43817)
Collaboration (1172)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1121)
CRISPR (88)
C-suite (565)
Cystic fibrosis (112)
Data (4365)
Denatured (15)
Depression (94)
Diabetes (257)
Diagnostics (1402)
Digital health (14)
Diversity (5)
Diversity, equity & inclusion (10)
Drug discovery (198)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31796)
Editorial (28)
Employer branding (4)
Employer resources (31)
Events (52108)
Executive appointments (628)
FDA (7652)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (1001)
Gene editing (186)
Generative AI (24)
Gene therapy (499)
GLP-1 (514)
Government (1185)
Grass and pollen (3)
Guidances (166)
Healthcare (6724)
HIV (18)
Huntington's disease (44)
IgA nephropathy (75)
Immunology and inflammation (198)
Immuno-oncology (43)
Indications (71)
Infectious disease (1231)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (170)
Interviews (25)
IPO (7369)
IRA (13)
Job creations (900)
Job search strategy (158)
JPM (40)
Kidney cancer (9)
Labor market (26)
Layoffs (247)
Leadership (10)
Legal (1449)
Liver cancer (42)
Longevity (11)
Lung cancer (427)
Lymphoma (251)
Machine learning (24)
Management (8)
Manufacturing (386)
MASH (133)
Medical device (2683)
Medtech (2692)
Mergers & acquisitions (6680)
Metabolic disorders (743)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (234)
Neuropsychiatric disorders (70)
Neuroscience (1978)
Neurotech (1)
NextGen: Class of 2026 (2091)
Non-profit (934)
Now hiring (31)
Obesity (341)
Opinion (131)
Ovarian cancer (133)
Pain (103)
Pancreatic cancer (166)
Parkinson's disease (232)
Partnered (12)
Patents (307)
Patient recruitment (345)
Peanut (44)
People (26891)
Pharmaceutical (44)
Pharmacy benefit managers (7)
Phase 1 (15506)
Phase 2 (20349)
Phase 3 (12880)
Pipeline (3364)
Policy (97)
Postmarket research (853)
Preclinical (6552)
Press Release (30)
Prostate cancer (148)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (664)
Real estate (1482)
Recruiting (13)
Regulatory (10000)
Reports (19)
Research institute (1003)
Resumes & cover letters (30)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (141)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2017)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (19)
The Weekly (64)
Vaccines (346)
Venture capital (70)
Weight loss (178)
Women's health (28)
Worklife (3)
Date
Today (20)
Last 7 days (317)
Last 30 days (1174)
Last 365 days (17893)
2026 (1970)
2025 (18169)
2024 (20602)
2023 (22516)
2022 (26948)
2021 (27925)
2020 (23491)
2019 (16478)
2018 (11963)
2017 (13870)
2016 (11986)
2015 (14500)
2014 (10476)
2013 (7571)
2012 (7647)
2011 (7725)
2010 (7504)
Location
Africa (164)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18373)
Australia (3131)
California (7152)
Canada (1865)
China (786)
Colorado (249)
Connecticut (255)
Delaware (238)
Europe (39470)
Florida (921)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (399)
India (36)
Indiana (163)
Iowa (8)
Japan (228)
Kansas (80)
Kentucky (10)
Louisiana (7)
Maine (11)
Maryland (743)
Massachusetts (5632)
Michigan (110)
Minnesota (251)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (36)
New Hampshire (21)
New Jersey (1662)
New Mexico (13)
New York (1781)
North Carolina (837)
North Dakota (6)
Northern California (3523)
Ohio (181)
Oklahoma (11)
Oregon (24)
Pennsylvania (1289)
Puerto Rico (9)
Rhode Island (27)
South America (226)
South Carolina (9)
Southern California (2834)
Tennessee (40)
Texas (925)
United States (23586)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (594)
West Virginia (1)
Wisconsin (46)
284,134 Results for "spark therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Spark Therapeutics Cuts 298 Employees as Part of Reorganization
Roche’s reorganization of Spark Therapeutics is coming more into focus, with nearly 300 employees being let go by the end of this year. Spark also trimmed its staff in 2024.
April 4, 2025
·
1 min read
·
Angela Gabriel
IPO
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
Nearly 100 biotechs went public amid the industry’s IPO frenzy in 2021, driven by an influx of pandemic-driven investments. But many of those companies have little to show investors.
February 4, 2026
·
11 min read
·
Tristan Manalac
Press Releases
SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression
January 21, 2026
·
4 min read
Gene therapy
Roche Absorbs $2.4B Impairment in Overhaul of Spark Gene Therapy Unit
Roche acquired Spark Therapeutics in 2019 for $4.8 billion.
March 11, 2025
·
2 min read
·
Tristan Manalac
gene therapy
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
Phacilitate’s annual event dawns as cell and gene therapies reach a new tipping point: the science has hit new heights just as regulatory and government policies spark momentum and frustration.
January 28, 2026
·
4 min read
·
Heather McKenzie
Press Releases
AcariaHealth Sparks Innovation at 2025 Healthcare Advocate Summit with Hackathon and Expert Panels
August 27, 2025
·
2 min read
Huntington’s disease
UniQure’s Regulatory Progress Sparks Optimism for ‘Desperate’ Huntington’s Space
Analysts reacted positively to the news that uniQure is in alignment with the FDA on an accelerated approval pathway and on target for a Q1 2026 submission for its one-time gene therapy for Huntington’s disease—but patients have been here before.
June 5, 2025
·
6 min read
·
Heather McKenzie
Pharmacy benefit managers
Trump’s Most Favored Nation Policy Sparks PBM Selloff
The Most Favored Nation directive would allow drugmakers to directly sell their products to patients at a lower cost, cutting out what President Donald Trump called “the middlemen.”
May 13, 2025
·
2 min read
·
Tristan Manalac
Huntington’s disease
FDA Does ‘About-Face’ on UniQure’s Huntington’s Gene Therapy
A month after sparking optimism for patients with Huntington’s disease with highly positive data for AMT-130, uniQure revealed Monday that the FDA may be changing its tune on the evidence required for an approval application, a change of direction Stifel called “very challenging” for uniQure.
November 3, 2025
·
3 min read
·
Heather McKenzie
Tariffs
Trump Tariff Pause Sparks Late-Day Rally for Pharma Stocks—But Not All
Pharma stocks went on a wild ride Wednesday amid whiplashing tariff threats from the U.S. president.
April 10, 2025
·
2 min read
·
Annalee Armstrong
1 of 28,414
Next
